Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Directorate Change

November 5, 2024
RNS Number : 8981K Renalytix PLC 05 November 2024 Renalytix plc ("Renalytix" or the "Company") Directorate Change Julian Baines MBE appointed as Executive Chairman LONDON and NEW YORK, 5 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Julian Baines MBE as Executive Chairman after shareholders approved the resolution

Holding(s) in Company

November 5, 2024
RNS Number : 8983K Renalytix PLC 05 November 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Ruffer LLP City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the

Holding(s) in Company

November 4, 2024
RNS Number : 8880K Renalytix PLC 04 November 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of financial instruments; An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name Pentwater Capital Management LP City of registered office (if applicable) Country of registered office (if applicable) US 4. Details of the shareholder Full name of

Directorate Change

October 31, 2024
RNS Number : 4687K Renalytix PLC 31 October 2024 Renalytix plc ("Renalytix" or the "Company") Directorate Change LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dan Levangie, Non-Executive Director has stepped down from the Board of Renalytix, effective immediately, following the General Meeting today.

Result of General Meeting

October 31, 2024
RNS Number : 4622K Renalytix PLC 31 October 2024 Renalytix plc ("Renalytix" or the "Company") Result of General Meeting LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, at the General Meeting ("GM") held earlier today, all resolutions were passed. Further details of each of the resolutions are set out in the

Posting of Circular & Notice of GM

October 11, 2024
RNS Number : 9446H Renalytix PLC 11 October 2024   Renalytix plc (" Renalytix " or the " Company ")   Posting of Circular and Notice of General Meeting   LONDON and NEW YORK , 11 October, 2024   ̶   Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics

Director/PDMR Shareholding

October 11, 2024
RNS Number : 7887H Renalytix PLC 11 October 2024     Renalytix plc ("Renalytix" or the "Company")   Director/PDMR Dealing   LONDON and NEW YORK , 11 October 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing

Holding(s) in Company

October 11, 2024
RNS Number : 7886H Renalytix PLC 11 October 2024   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non- UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3.

Holding(s) in Company

October 11, 2024
RNS Number : 7884H Renalytix PLC 11 October 2024   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non- UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3.

Holding(s) in Company

October 9, 2024
RNS Number : 5976H Renalytix PLC 09 October 2024   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing

Admission of Shares & Total Voting Rights

October 8, 2024
RNS Number : 4004H Renalytix PLC 08 October 2024   Renalytix plc (" Renalytix " or the " Company ")   Admission of Shares & Total Voting Rights   Renalytix (AIM: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to

Commencement of trading on OTCQB in the United States

October 8, 2024
Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro

Commencement of trading on OTCQB in the US

October 8, 2024
RNS Number : 3346H Renalytix PLC 08 October 2024     Renalytix plc ("Renalytix" or the "Company")   Commencement of trading on OTCQB in the United States   Renalytix plc American Depository Shares (ADSs) begin trading on   OTCQB Venture Market under symbol "RNLXY" effective from Market Open on

Result of Placing and Subscription

October 1, 2024
RNS Number : 4887G Renalytix PLC 01 October 2024   THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE

Audited US GAAP financial results

October 1, 2024
RNS Number : 4130G Renalytix PLC 01 October 2024     Renalytix plc ("Renalytix" or the "Company")   Audited US GAAP financial results for the fiscal year ended 30 June 2024   LONDON and NEW YORK , 1 October, 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in
Displaying 1 - 10 of 605